evidenceId,evidenceType,shortDesc,desc,id,lastEdit,status,gene/entrezGeneId,gene/hugoSymbol,gene/name,gene/oncogene,gene/curatedIsoform,gene/curatedRefSeq,gene/geneAliases/0,gene/geneAliases/1,gene/geneAliases/2,gene/geneAliases/3,gene/geneAliases/4,gene/geneAliases/5,gene/geneAliases/6,gene/tsg,articles/0/pmid,articles/0/title,articles/0/journal,articles/0/pubDate,articles/0/volume,articles/0/issue,articles/0/pages,articles/0/authors,articles/0/elocationId,articles/0/link,articles/0/reference,articles/0/abstract,articles/1/pmid,articles/1/title,articles/1/journal,articles/1/pubDate,articles/1/volume,articles/1/issue,articles/1/pages,articles/1/authors,articles/1/elocationId,articles/1/link,articles/1/reference,articles/1/abstract,articles/2/pmid,articles/2/title,articles/2/journal,articles/2/pubDate,articles/2/volume,articles/2/issue,articles/2/pages,articles/2/authors,articles/2/elocationId,articles/2/link,articles/2/reference,articles/2/abstract
5005,GENE_SUMMARY,,"IDH1, a cell metabolism enzyme, is recurrently mutated in various cancers including acute myeloid leukemia and gliomas.",,2017-04-28,,3417,IDH1,"isocitrate dehydrogenase (NADP(+)) 1, cytosolic",True,ENST00000345146,NM_005896.2,IDP,HEL-216,IDH,IDPC,IDCD,HEL-S-26,PICD,False,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
5006,GENE_BACKGROUND,,"The IDH1 (isocitrate dehydrogenase 1) protein is an enzyme that catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG), a crucial step in the tricarboxylic acid (TCA) cycle. IDH1 utilizes NADP(+) as an electron acceptor and it is predominantly expressed in the cytosol and peroxisomes, playing a role in the cytoplasmic production of NADPH. Cancer-associated mutations in the catalytic site of IDH1 confer a gain-of-function of neomorphic enzymatic activity, allowing the mutant enzyme to convert α-KG to the “oncometabolite” D-2-hydroxyglutarate (2-HG) (PMID: 20171147). 2-HG promotes tumor development by inhibiting a variety of enzymes that require α-KG as a substrate, including enzymes involved in DNA demethylation, histone demethylation, adaptation to hypoxia and collagen maturation. IDH1 mutations have been identified in glioma, cholangiocarcinoma and acute myeloid leukemia (AML) among others (PMID: 19657110, 23630074).",,2017-08-02,,3417,IDH1,"isocitrate dehydrogenase (NADP(+)) 1, cytosolic",True,ENST00000345146,NM_005896.2,IDP,HEL-216,IDH,IDPC,IDCD,HEL-S-26,PICD,False,19657110,Recurring mutations found by sequencing an acute myeloid leukemia genome.,The New England journal of medicine,2018-09-10T20:09:00,361,11,1058-66,Mardis ER et al,doi: 10.1056/NEJMoa0903840,,0001-09-10,,23630074,"What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.",Genes &amp; development,2018-04-15T20:13:00,27,8,836-52,Losman JA et al,doi: 10.1101/gad.217406.113,,0001-04-15,,20171147,The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.,Cancer cell,2018-03-16T20:10:00,17,3,225-34,Ward PS et al,doi: 10.1016/j.ccr.2010.01.020,,0001-03-16,
